EVIDENCEML

Serial Number 98774471
661

Registration Progress

Application Filed
Sep 27, 2024
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

EVIDENCEML

Basic Information

Serial Number
98774471
Filing Date
September 27, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
661
Status Date
Jul 8, 2025
Application
Pending
Classes
009 042

Rights Holder

EntityRisk, Inc.

03
Address
300 Carnegie Center Suite 150
Princeton, NJ 08540

Ownership History

EntityRisk, Inc.

Original Applicant
03
Princeton, NJ

Legal Representation

Attorney
Tracy Wells

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

9 events
Date Code Type Description Documents
Jul 8, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 7, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 7, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 7, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 7, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 7, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 3, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 2, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 27, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 009
Computer software platforms, downloadable, for predicting asset values, determining pricing, evidence-generation, and contracting by utilizing a pricing and generalized value module and commercial due diligence module; Computer software platforms, downloadable, for use in building financial recommendations based on clinical evidence of benefit and risk, expediting value assessment, and providing a qualitative evidence based financial approach to support decisions about pricing, evidence generation and contracting; Computer software platforms, downloadable, for use in simulating expected commercial opportunities and downside risks utilizing alternative clinical and real-world evidence-generation strategies from to optimize endpoint selection and evidence generation
First Use Anywhere: May 5, 2024
First Use in Commerce: May 5, 2024
Class 042
Design, development, and implementation of software for predicting asset values, determining pricing, evidence-generation, contracting by utilizing a pricing and generalized value module and commercial due diligence module, building financial recommendations based on clinical evidence of benefit and risk, expediting value assessment, and providing a qualitative evidence based financial approach to support decisions about pricing, evidence generation and contracting; Providing an interactive website featuring technology that allows users to enter, access, and synthesize information and generate reports for use in consulting with executives and businesses; Software as a service (SAAS) featuring software for predicting business asset values, determining pricing, evidence generation, and contracting by utilizing a pricing and generalized value module and commercial due diligence module
First Use Anywhere: May 5, 2024
First Use in Commerce: May 5, 2024

Additional Information

Pseudo Mark
EVIDENCE ML
Pseudo Mark
EVIDENCE M L; EVIDENCE MACHINE LEARNING

Classification

International Classes
009 042